• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Automatiqc
    • Datacise
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
New FDA Guidance to Support Ultra-Rare Disease Drug Development

New FDA Guidance to Support Ultra-Rare Disease Drug Development

by Olivia Grant | Jan 10, 2022 | Blog

New FDA Guidance to Support Ultra-Rare Disease Drug Development by Dr. Amanda Beaster, Senior Manager of Regulatory Strategy Antisense oligonucleotide (ASO) drug products target a specific sense mRNA to modulate gene expression in living cells and have been...
Praxis bioresearch seeks support from MMS for Alzheimers Disease Therapeutics

Praxis bioresearch seeks support from MMS for Alzheimers Disease Therapeutics

by Olivia Grant | Oct 28, 2021 | News

Praxis Bioresearch Seeks Regulatory Strategy Support from MMS Holdings to Develop Therapeutics for Alzheimer’s Disease   SACRAMENTO, Calif. (October 28, 2021) – MMS Holdings (MMS) – a data-focused CRO – provided regulatory strategy support to Praxis...

Recent Posts

  • MMS Holdings Only Michigan Pharma Organization Awarded a 2022 Top Workplace USA Recognition
  • FDA’s Recent Benefit Risk Assessment Guidance Explained: What It Means for Sponsors
  • New FDA Guidance to Support Ultra-Rare Disease Drug Development
  • Looking back at 2021 – MMS Holdings year in review
  • MMS Strengthens Leadership in the Area of Project Advisory Services

Tags

Alzheimers Alzheimers Disease Therapeutics biostatistics clinical research clinical study reports clinical trials clinical trial transparency Compliance COVID-19 CRO data management data science decentralized clinical trials drug development EMA FDA FSP Functional Service Provider (FSP) GXP auditing Health Analytics Collective Health Canada IND submission innovation Lay summaries leadership machine learning Machine Learning in Clinical Research medical writing MMS Academy NDA submission News opioids Orphan Drug Designation Applications pharmacovigilance PhUSE quality control rare disease real world data regulatory operations regulatory quality control REMS RWE statistical programming transparency Volunteering
Clicking “Accept” will allow us to store cookies on your device to enhance website navigation, analyze site usage, and improve communications. Settings can be adjusted at any time through the “Cookie Settings” link.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT